Inventor · disambiguated record
Cynthia Seidel-Dugan
Also filed as: SEIDEL-DUGAN CYNTHIA
17 granted patents·26 pending applications·73 citations·filing 2002–2025
92Inventor score
Files withWEREWOLF THERAPEUTICS INC23POTENZA THERAPEUTICS INC7TRIEZA THERAPEUTICS INC4MERCK SHARP & DOHME2WANG YAOLIN2
Top patents by PatentIndex Score
43 records- 0196US11352403B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Jun 7, 2022·6 cites·13 claims
- 0296US10696724B2Activatable interleukin-2 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·18 cites·11 claims
- 0395US10696723B2Activatable interleukin 12 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·15 cites·12 claims
- 0494US11535658B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·2 cites·21 claims
- 0593US11981716B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted May 14, 2024·2 cites·13 claims
- 0691US10232053B2Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·23 cites·5 claims
- 0783US10227413B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Mar 12, 2019·2 cites·20 claims
- 0882US10507244B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2017·Granted Dec 17, 2019·3 cites·24 claims
- 0982US2024358796A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1081US11186644B2Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2019·Granted Nov 30, 2021·1 cites·11 claims
- 1179US12076371B2Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Granted Sep 3, 2024·0 cites·29 claims
- 1278US12275769B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Apr 15, 2025·0 cites·14 claims
- 1378US12036266B2Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Jul 16, 2024·0 cites·19 claims
- 1478US2024262880A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1575US11739132B2Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Aug 29, 2023·0 cites·16 claims
- 1675US2024174725A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1774US2025179138A1Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1874US2023272028A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1974US2023051423A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2070US11453710B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·0 cites·16 claims
- 2168US2022098312A1Anti-neuropilin antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2268US2021393803A1Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2365US2024216470A1Inducible il-2 and pd-1/pd-l1 combination therapyWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2465US2024216505A1Inducible cytokine prodrug and pd-1/pd-l1 combination therapyWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2565US2024216474A1Activatable interferon polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2664US8470297B1FDG-pet evaluation of Ewing's sarcoma sensitivityLU BRIAN DERHUA·Filed 2010·Granted Jun 25, 2013·1 cites·21 claims
- 2764US2021130430A1Activatable cytokine polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2862US2021115102A1Separation moieties and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2961US2020014798A1Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancerTRIEZA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3060US2024043488A1Activatable il-12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3159US2024374687A1Il-2 prodrugWEREWOLF THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3258US2021269542A1Anti-gitr antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3356US2013243692A1Fdg-pet evaluation of ewing's sarcoma sensitivityMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 3452US10988545B2Anti-GITR antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Apr 27, 2021·0 cites·11 claims
- 3552US2019142967A1Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of CancerTRIEZA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3650US2011091524A1Biomarkers for sensitivity to anti-igf1r therapyWANG YAN·Filed 2008·Application pending·0 cites
- 3750US2014336222A1SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOFMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 3849US2011104256A1Methods for treating or preventing colorectal cancerWANG YAOLIN·Filed 2009·Application pending·0 cites
- 3948US2011129456A1Sequential Administration of Chemotherapeutic Agents for Treatment of CancerWANG YAOLIN·Filed 2009·Application pending·0 cites
- 4044US2011262525A1Methods of treatmentSCHERING CORP·Filed 2007·Application pending·0 cites
- 4140US11453720B2Anti-TIGIT antigen-binding proteins and methods of use thereofPOTENZA THERAPEUTICS INC·Filed 2018·Granted Sep 27, 2022·0 cites·21 claims
- 4233US2006088829A1Minrs as modifiers of insulin receptor signaling and methods of useBRACE ARTHUR·Filed 2003·Application pending·0 cites
- 4333US2004101879A1Srebp pathway modulation through targeting hisrsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cynthia Seidel-Dugan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →